impact on neurological comorbidities

This retrospective study evaluates the severity and outcome of COVID-19 in MS and characterizes temporal trends over the course of the pandemic in the United States.

The authors developed an interferon (IFN)-γ release assay to detect T-cell responses specific to SARS-CoV-2 after overnight stimulation of whole blood with peptide libraries covering the immunodominant sequence domains of the Spike glycoprotein and the Nucleocapsid phosphoprotein.

In this article the authors systematically reviewed and meta-analyzed variations in stroke admissions, rate and timing of reperfusion treatments during the 1st-wave COVID pandemic versus the pre-pandemic timeframe depending on stroke network model adopted.

The aim of this study was to determine the influence of high-efficacy disease modifying therapy on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis.